In the phase 2 trial, the drug was administered by intravenous infusion once a month at three ... biologic agents led by Pfizer's tanezumab and Regeneron's fasinumab that showed promise in ...

Crovalimab will try to muscle into a market dominated by AZ's Soliris and follow-up C5 drug Ultomiris (ravulizumab), which only needs to be given by infusion every eight weeks. Soliris and ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: January 31 at 7:53:39 p.m. EST ...